查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594468

神經疼痛治療藥物市場：按治療方法、適應症、分銷管道 - 全球預測 2025-2030

Neuralgia Treatment Market by Treatment (Drug-Based, Surgery), Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

根據預測，2023年神經痛治療市場價值為10.6億美元，預計到2024年將達到12億美元，複合年成長率為12.41%，到2030年將達到24.2億美元。

神經痛藥物是指治療和緩解神經損傷、發炎和功能障礙引起的神經疼痛，常見於三叉神經痛和帶狀皰疹後遺症神經痛等疾病。對神經止痛藥物的需求源於受影響個體的嚴重不適和生活品質下降，從而推動了對有效解決方案的持續需求。這些治療方法範圍從抗驚厥藥和抗憂鬱症等藥物到神經阻斷、神經調節甚至手術介入等先進治療方法。最終用戶包括醫院、疼痛管理中心以及神經內科和神經外科診所。神經病變疼痛疾病的增加、患者意識的提高以及藥物開發和醫療技術的進步推動了市場的開拓。然而，治療成本高、長期用藥帶來的副作用以及缺乏明確治療方法等挑戰可能會阻礙市場擴張。此外，低收入地區獲得醫療保健的機會有限可能會限制治療的採用。機會存在於創新領域，例如開發非侵入性神經調節劑、新型藥物傳輸系統以及針對個人基因組成的個人化醫療方法。公司還可以探索人工智慧和機器學習，以增強診斷和治療策略。鼓勵官民合作關係並投資於研究，以最大限度地降低成本，同時最大限度地發揮影響力，也可以帶來顯著的好處。儘管有這些機會，監管障礙和臨床試驗的耗時性質仍然是重大障礙。競爭情勢市場正在經歷快速的技術進步和各大公司爭奪市場佔有率的競爭環境，需要不斷的技術創新。持續監測新興趨勢，例如患者對微創治療的偏好和疼痛管理的整體方法，對於希望利用這個動態市場的公司至關重要。

主要市場統計
基準年[2023] 10.6億美元
預測年份 [2024] 12億美元
預測年份 [2030] 24.2億美元
複合年成長率（%） 12.41%

市場動態：揭示快速發展的神經疼痛藥物市場的關鍵市場洞察

供需的動態交互作用正在改變神經止痛藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 由於人口老化，神經痛的發生率增加
    • 政府努力提高人們對神經疼痛治療產品的認知
  • 市場限制因素
    • 神經疼痛治療高成本
  • 市場機會
    • 技術進步將消除對藥物和手術的需求
    • 新興經濟體外科和藥物治療的發展
  • 市場挑戰
    • 藥物的持續副作用

波特的五力：駕馭神經疼痛藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對神經痛治療市場的影響

外部宏觀環境因素在塑造神經痛治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解神經疼痛治療藥物市場的競爭狀況

神經疼痛治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣神經痛治療市場供應商的績效評估

FPNV定位矩陣是評估神經痛治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃神經疼痛治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對神經疼痛治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 隨著年齡的成長，神經痛的發生率增加
      • 政府採取措施提高人們對神經疼痛治療產品的認知
    • 抑制因素
      • 治療神經痛費用高
    • 機會
      • 技術進步將消除對藥物和手術的需求
      • 新興經濟體外科和藥物治療的發展
    • 任務
      • 藥物的持續副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療方式分類的神經痛治療藥物市場

  • 基於藥物的
    • 抗驚厥藥
    • 三環抗憂鬱藥物
  • 外科手術
    • 球囊壓縮
    • 甘油注射液
    • 微血管減壓手術
    • 射頻燒傷治療
    • 立體放射線手術

第7章依適應症分類的神經痛治療藥物市場

  • 糖尿病神經病變
  • 肋間神經痛
  • 枕神經痛
  • 周邊神經痛
  • 帶狀皰疹後遺症神經痛
  • 三叉神經痛

第8章神經痛治療藥物市場：依通路分類

  • 藥局
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章 北美、南美神經痛治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太神經痛治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲神經痛治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Biogen Inc.
  • Cadila Healthcare
  • GLENMARK PHARMS LTD.
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals, Inc.
  • Lupin Limited
  • Merz Pharma GmbH & Co. KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Teikoku Pharma USA, Inc.
  • Teva Pharmaceuticals Ltd.
  • Torrent Pharmaceuticals Ltd.
  • UCB Group
Product Code: MRR-F74E250AD635

The Neuralgia Treatment Market was valued at USD 1.06 billion in 2023, expected to reach USD 1.20 billion in 2024, and is projected to grow at a CAGR of 12.41%, to USD 2.42 billion by 2030.

Neuralgia treatment refers to the management and alleviation of nerve pain, which may arise due to damaged, irritated, or dysfunctional nerves often seen in conditions like trigeminal neuralgia and postherpetic neuralgia. The necessity of neuralgia treatment stems from the significant discomfort and reduced quality of life for affected individuals, fueling an ongoing demand for effective solutions. The application of these treatments spans pharmaceuticals, such as anticonvulsants and antidepressants, to advanced therapies like nerve blocks, neuromodulation, and even surgical interventions. End-users comprise hospitals, pain management centers, and specialty clinics dedicated to neurology and neurosurgery. Market growth is being driven by increasing incidences of neuropathic pain conditions, growing patient awareness, and advancements in drug development and medical technologies. However, challenges like high treatment costs, side effects associated with long-term medication use, and a lack of definitive cures can impede market expansion. Furthermore, limited healthcare access in low-income regions can restrict treatment uptake. Opportunities lie in innovative areas like developing non-invasive neuromodulation devices, novel drug delivery systems, and personalized medicine approaches tailored to an individual's genetic makeup. Companies can also explore artificial intelligence and machine learning to enhance diagnosis and treatment strategies. Encouraging public-private partnerships and investing in research to minimize costs while maximizing efficacy can also yield substantial benefits. Despite these opportunities, regulatory hurdles, and the time-consuming nature of clinical trials remain considerable barriers. The neuralgia treatment market is characterized by rapid technological advancements and a competitive landscape where major players vie for market share, prompting constant innovation. Continually monitoring emerging trends, such as patient preferences for minimally invasive treatments and holistic approaches to pain management, will be crucial for businesses aiming to capitalize on this dynamic market.

KEY MARKET STATISTICS
Base Year [2023] USD 1.06 billion
Estimated Year [2024] USD 1.20 billion
Forecast Year [2030] USD 2.42 billion
CAGR (%) 12.41%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuralgia Treatment Market

The Neuralgia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of neuralgia due to the rise in the aging population
    • Government initiatives to spread awareness regarding neuralgia treatment products
  • Market Restraints
    • High-cost associated with the treatment of neuralgia
  • Market Opportunities
    • Technological advancement eliminates the need for drugs and surgery
    • Developing surgical and pharmacological treatment in developing economies
  • Market Challenges
    • Persistent side effects from medications

Porter's Five Forces: A Strategic Tool for Navigating the Neuralgia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuralgia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuralgia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuralgia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuralgia Treatment Market

A detailed market share analysis in the Neuralgia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuralgia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuralgia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuralgia Treatment Market

A strategic analysis of the Neuralgia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuralgia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Biogen Inc., Cadila Healthcare, GLENMARK PHARMS LTD., H. Lundbeck A/S, Janssen Pharmaceuticals, Inc., Lupin Limited, Merz Pharma GmbH & Co. KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teikoku Pharma USA, Inc., Teva Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., and UCB Group.

Market Segmentation & Coverage

This research report categorizes the Neuralgia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Drug-Based and Surgery. The Drug-Based is further studied across Anticonvulsant Medicines and Tricyclic Antidepressants. The Surgery is further studied across Balloon Compression, Glycerol Injection, Microvascular Decompression, Radiofrequency Thermal Lesioning, and Stereotactic Radiosurgery.
  • Based on Indication, market is studied across Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, and Trigeminal Neuralgia.
  • Based on Distribution Channel, market is studied across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of neuralgia due to the rise in the aging population
      • 5.1.1.2. Government initiatives to spread awareness regarding neuralgia treatment products
    • 5.1.2. Restraints
      • 5.1.2.1. High-cost associated with the treatment of neuralgia
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement eliminates the need for drugs and surgery
      • 5.1.3.2. Developing surgical and pharmacological treatment in developing economies
    • 5.1.4. Challenges
      • 5.1.4.1. Persistent side effects from medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neuralgia Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Drug-Based
    • 6.2.1. Anticonvulsant Medicines
    • 6.2.2. Tricyclic Antidepressants
  • 6.3. Surgery
    • 6.3.1. Balloon Compression
    • 6.3.2. Glycerol Injection
    • 6.3.3. Microvascular Decompression
    • 6.3.4. Radiofrequency Thermal Lesioning
    • 6.3.5. Stereotactic Radiosurgery

7. Neuralgia Treatment Market, by Indication

  • 7.1. Introduction
  • 7.2. Diabetic Neuropathy
  • 7.3. Intercostal Neuralgia
  • 7.4. Occipital Neuralgia
  • 7.5. Peripheral Neuralgia
  • 7.6. Postherpetic Neuralgia
  • 7.7. Trigeminal Neuralgia

8. Neuralgia Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Drug Stores
  • 8.3. Hospital Pharmacies
  • 8.4. Online Pharmacies
  • 8.5. Retail Pharmacies

9. Americas Neuralgia Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Neuralgia Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Neuralgia Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Biogen Inc.
  • 3. Cadila Healthcare
  • 4. GLENMARK PHARMS LTD.
  • 5. H. Lundbeck A/S
  • 6. Janssen Pharmaceuticals, Inc.
  • 7. Lupin Limited
  • 8. Merz Pharma GmbH & Co. KGaA
  • 9. Novartis AG
  • 10. Pfizer Inc.
  • 11. Takeda Pharmaceutical Company Limited
  • 12. Teikoku Pharma USA, Inc.
  • 13. Teva Pharmaceuticals Ltd.
  • 14. Torrent Pharmaceuticals Ltd.
  • 15. UCB Group

LIST OF FIGURES

  • FIGURE 1. NEURALGIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. NEURALGIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEURALGIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. NEURALGIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. NEURALGIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEURALGIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEURALGIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEURALGIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTICONVULSANT MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY BALLOON COMPRESSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY GLYCEROL INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY MICROVASCULAR DECOMPRESSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY RADIOFREQUENCY THERMAL LESIONING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INTERCOSTAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY OCCIPITAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PERIPHERAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY DRUG-BASED, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 240. NEURALGIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 241. NEURALGIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023